Gland Pharma is one of the world’s largest manufacturers of generic sterile injectables - the kind of drugs that go directly into the bloodstream through a syringe or IV bag - and it has spent nearly five decades quietly becoming the factory behind the counter for some of the biggest pharmaceutical names on the planet. Founded in Hyderabad in 1978 to make a single blood-thinner injection for India, the company now ships complex, hard-to-make injectable medicines to over 60 countries, operating a business model where it either owns the drug formula and licenses it out, or builds and fills the product for a partner who puts their own label on it. The recurring approach that explains everything else is a “Quality First” obsession paired with relentless cost discipline - the company runs its own API (active pharmaceutical ingredient) plants to control raw-material costs, maintains a spotless regulatory record with no US FDA warning letters across any of its facilities, and designs its production lines to switch between products so that one factory can serve dozens of customers without expensive retooling.
Business segments
A single engine with two complementary ways to get paid - owning the intellectual property and sharing the profits, or charging a fixed fee to make someone else’s product - both running on the same manufacturing backbone.
1. Generic injectables and CDMO: the factory that works for everyone
The company makes sterile injectable medicines - vials, pre-filled syringes, IV bags, ampoules - and earns revenue either by selling its own approved drugs through partners or by manufacturing for other pharmaceutical companies under long-term contracts, with the two models sharing the same production lines and quality infrastructure.
- Owns the formula, shares the profit - in its B2B IP-led model, Gland develops a generic drug, files for regulatory approval under its own name, and then licenses the rights to a marketing partner under a 3-5 year supply contract; it collects a licence fee, a fixed selling price per unit, and a share of the partner’s profit, with the profit-share portion making up roughly 10% of revenue. Because the transfer price is immune to raw-material cost swings, the model protects Gland from input-price volatility, and price erosion in the end market only hits the profit-share slice, not the whole sale.
- Paid per unit to fill and finish - through its B2B CMO (contract manufacturing) model, Gland provides sterile fill-and-finish services for other companies’ injectable products, charging a fixed per-unit price while the customer keeps ownership of the dossier, the intellectual property, and the marketing rights. This turns Gland into a dedicated production line for “billion-dollar players” who find it uneconomical to build their own capacity for smaller-volume injectables.
- Co-develops and collects royalties - under the tech-transfer model, Gland co-develops a product with a partner and then manufactures it, earning a tech-transfer fee upfront plus a per-unit selling price and ongoing royalties; this is how the company has built its CDMO (contract development and manufacturing) pipeline, which now accounts for 46% of total revenues.
- Sells directly to Indian hospitals - in its home market, Gland runs a targeted B2C operation, marketing its own branded injectables directly to approximately 4,000 corporate hospitals, nursing homes, and government facilities through a dedicated sales team and a nationwide distribution network. This is the smallest revenue stream but gives the company a direct line to end-customers in a fast-growing healthcare market.
- The US is the anchor, but the map is global - the United States contributes 53-54% of group revenue, and Gland has direct relationships with 13 of the top 15 US generic injectables companies, with its top 10 customer relationships stretching back more than eight years. Beyond the US, the company exports to 60-plus countries, with Europe, Canada, Australia, and New Zealand contributing 4% of revenue and the Rest of the World - including a recently won tender in Saudi Arabia for 15 products - contributing 17-19%.
2. Cenexi: the European CDMO bridgehead
Acquired in April 2023, Cenexi is a wholly-owned French-Belgian contract manufacturer that gives Gland a European manufacturing footprint, a customer base hungry for sterile injectables and hormonal drugs, and a turnaround story that has just reached operational stability.
- Turnaround is delivering - Cenexi was acquired in a transitional phase with frequent breakdowns, low-margin products, and delayed tech transfers; Gland launched a phased transformation plan covering everything from preventive maintenance and weekend shifts to a leaner corporate structure and contract renegotiations. By the fourth quarter of FY26, Cenexi was operationally stable and EBITDA-positive, recording €1 million in EBITDA and €182 million in full-year revenue.
- One platform, two continents - Gland and Cenexi are now integrated in business development and customer engagement, operating as “one unified platform” that lets the company bid for larger multi-geography contracts that neither could win alone. Cross-selling is underway, with Cenexi identifying opportunities inside Gland’s existing customer base.
Manufacturing and quality backbone
Seven Indian factories - four for finished injectables, three for active pharmaceutical ingredients - plus four European sites form a production network designed for flexibility, with 32 lines that can switch between products and a quality workforce of over 1,400 people that has kept every facility free of US FDA warning letters since inception.
- Vertical integration starts with the raw material - the four in-house API facilities at Visakhapatnam and Hyderabad produce roughly 11,000 kilograms of active ingredients per year, supplying critical starting materials for 28 of the company’s own ANDAs (abbreviated new drug applications) and insulating Gland from supply-chain disruptions and third-party price mark-ups.
- Lines built to flex - the finished-formulation sites house 28 production lines with a combined capacity of approximately 1,000 million units per year, and the manufacturing processes are deliberately designed to be flexible and scalable so that new products can be added without major modifications to existing equipment.
- Quality is a third of the workforce - around 35-37% of employees - 1,473 full-time staff - are dedicated to quality control and assurance, and the company undergoes over 40 customer and regulatory audits annually, with internal audits conducted quarterly across every facility.
- Regulatory track record is the moat - all manufacturing facilities are certified GMP-compliant by the US FDA, and the company has never received a warning letter since each facility began operations, a record reinforced in early 2025 when the FDA closed out inspections at both the Dundigal and Pashamylaram sites with no adverse findings.
Group structure and partners
Gland Pharma is majority-owned by Shanghai Fosun Pharma, which bought a 74% stake in 2017 and provides access to the Chinese market, raw-material sourcing scale, and board-level representation, while the operating structure runs through a Singapore holding company that owns the US and European subsidiaries.
- Fosun is the controlling shareholder - Shanghai Fosun Pharmaceutical Group, listed in Shanghai and Hong Kong, acquired its stake to give Gland widened market access, regulatory know-how for China, and bargaining power for raw materials and equipment sourced from China. Post-acquisition, Gland leveraged the Fosun network to grow sales in some African markets and began actively pursuing the China market, where it has filed nine products and commercialised one.
- The international structure runs through Singapore - Gland Pharma International Pte. Ltd., a wholly-owned Singapore subsidiary, holds Gland Pharma USA and the French and Belgian entities that operate Cenexi, with the Cenexi group structured under Phixen SAS and its subsidiaries Cenexi SAS, Cenexi Services SAS, Cenexi HSC SAS, and Cenexi Laboratories Thissen SA in Belgium.
- Fosun places directors on the board - as of FY26, two Fosun-affiliated directors serve as Non-Executive and Non-Independent members: Mr. Wenjie Zhang, Executive President and Co-CEO of Fosun Pharma’s Innovative Medicines division, and Ms. Wei Huang, President of Shanghai Henlius Biotech, who brings over 30 years of experience in process development, manufacturing, and quality systems. Independent directors make up 56% of the board.